ERS International Congress 2017 - European Respiratory Society

ERS International Congress 2017
The European Respiratory Society (ERS; is an international organisation that brings together physicians, healthcare professionals, scientists and other experts working in respiratory medicine. We are one of the leading medical organisations in the respiratory field, with a growing membership representing over 140 countries worldwide.








1. Clinical

  • Interstitial lung diseases
  • CT for pneumologists
  • Clinical problems solving
  • Interventional pulmonology
  • Sarcoidosis
  • Biopsy options
  • Lung cancer screening

2. Respiratory intensive care

  • NIV vs. HFNC for hypoxemic patients
  • Expanding NIV indication for weaning purposes: patient populations, modes of ventilation, interfaces, sedatives)
  • Long term mechanical ventilation in COPD: which markers should we consider? How should we monitor? Where should we start it?
  • Beyond flow, volume and airway pressure: which signals should we consider today for the ventilatory management of critically-ill patients
  • Bedside imaging of the critically ill patient
  • Weaning ten years later: are the statements of the Sixth International Consensus Conference on Intensive Care Medicine about Weaning still valid?
  • Non-invasive ventilation vs. High Flow Nasal Cannula
  • Hospital-acquired and ICU-acquired pneumonia
  • What outcome for mechanically ventilated patients?

3. Cell and molecular biology

  • Immunity and the Lung
  • The Lung Microbiome
  • Stem Cells in Lung Diseases
  • Lung Matrix
  • Emphysema

4. Clinical physiology, sleep and pulmonary circulation

  • New paradigms in the diagnosis of sleep apnoea
  • Interaction of sleep apnoea and respiratory failure
  • Deleterious/protective effects of intermittent hypoxia in OSA
  • From brain to cardiopulmonary interaction passing through locomotor muscles: the origin and mechanisms of exertional dyspnoea in cardiorespiratory diseases
  • Respiratory muscle at rest and during exercise: What's new?
  • Mild COPD: physiology, clinical implications, treatment....where are we?
  • Respiratory muscle testing: an update

5. Airway diseases

  • Immunity in asthma and COPD
  • Eosinophili inflammation in COPD
  • Non-invasive assessment of airway inflammation
  • Pharmacological treatment in bronchiectasis
  • Personalised medicine in airway disease
  • Blood eosinophilia in COPD
  • Non-invasive technique to assess airway inflammation
  • ICS in COPD: how, when, why
  • Chronic cough and eosinophili bronchitis

6. Occupation and epidemiology

  • Lung cancer screening
  • Microbiota and lung disease
  • Smoking cessation
  • Statistical methods in epidemiology
  • Gene-environment interactions and the individual patient
  • Prediction rules for asthma and COPD
  • The respiratory microbiome and the environment
  • How can we keep individuals with respiratory disease at work

7. Paediatrics

  • Bronchiolitis and preschool wheezing
  • Asthma
  • Microbioma in respiratory infections
  • Lung Function Tests
  • Non-CF bronchiectasis and PCD
  • Acute and chronic respiratory infection

8. Thoracic surgery and transplantation

  • Difficult lung transplant indications
  • Donors for lung transplantation in 2017: where are we?
  • Lung transplantation and cancer
  • Difficult pulmonary infections: what have we learned from lung transplantation?
  • Key points of the preoperative selection for marginal surgical candidates
  • What is the optimal multimodality treatment for lung cancer?
  • Medistinal problems
  • Mesothelioma
  • Pneumothorax
  • Bronchiectasis - localised form
  • Undetermined lung nodules

9. Allied respiratory professionals

  • Relevant outcomes to measure in chronic disease management
  • Pulmonary rehabilitation
  • New techniques in diagnosing respiratory diseases
  • Self-management in respiratory disease
  • Muscle function and structure in COPD
  • Care models for chronic lung disease

10. Respiratory infections

  • Pneumonia
  • Antimicrobial resistance
  • New anti-TB drugs
  • Influenza and viral infections
  • New diagnostics, including whole genome sequencing, for the TB diagnosis
  • LTBI
  • Challenges in LTBI management
  • Microbial phenotypes in chronic airway diseases
  • Clinical impact of NTM
  • Global perspective on ILI
  • New and repurposed anti-TB drugs

11. Thoracic oncology

  • Update on immuno-therapies and its combinations with standard therapies in lung cancer
  • Rational diagnostic work-up of lung cancer at the time of first diagnosis and relapse – What do we need to know to treat our patients and how do we get the needed information? - Interventional techniques
  • Rational diagnostic work-up of lung cancer at the time of first diagnosis and relapse – What do we need to know to treat our patients and how do we get the needed information? - Molecular pathology
  • The new TNM-staging system and beyond – predicting lung cancer prognosis
  • Rational diagnostic work-up of lung cancer at the time of first diagnosis and relapse – What do we need to know to treat our patients and how do we get the needed information? - Imaging techniques
  • Update on malignant pleural mesothelioma
  • Early integration of palliative care in thoracic oncology patients – has the goal been really achieved yet?
  • How to evaluate fitness for therapy in lung cancer patients and how to follow them up after surgery, radiotherapy and/or chemotherapy
  • Early integration of palliative care for lung cancer patients
  • Deliver bad news
  • Immunotherapy in interaction with Anti-VEGF stategies
  • Therapeutic sequences for lung cancer treatment
  • Infectious and immunological complications during lung cancer treatment

Related articles

More events

ESRA 2024

Wed, 4 Sep 2024 - Sat, 7 Sep 2024

5. května 1640
Prague 4, 140 00
Czech Republic
ERS Congress 2024

Sat, 7 Sep 2024 - Wed, 11 Sep 2024

Messeplatz 1
Wien, 1020